Christine Hunt

List of Publications by Citations

Source: https://exaly.com/author-pdf/5685906/christine-hunt-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32 papers	2,049 citations	19 h-index	37 g-index
37 ext. papers	2,338 ext. citations	5.4 avg, IF	4.35 L-index

#	Paper	IF	Citations
32	Case definition and phenotype standardization in drug-induced liver injury. *Clinical Pharmacology and Therapeutics*, **2011**, 89, 806-15	6.1	563
31	Effect of age and gender on the activity of human hepatic CYP3A. *Biochemical Pharmacology*, **1992**, 44, 275-83	6	356
30	Clinical relevance of hepatitis B viral mutations. *Hepatology*, **2000**, 31, 1037-44	11.2	288
29	Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. *Hepatology*, **2000**, 32, 135-8	11.2	138
28	Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. *Drug Safety*, **2010**, 33, 503-22	5.1	110
27	Effect of orthotopic liver transplantation on employment and health status. *Liver Transplantation*, **1996**, 2, 148-53		53
26	Drug-induced liver injury following positive drug rechallenge. *Regulatory Toxicology and Pharmacology*, **2009**, 54, 84-90	3.4	45
25	Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. *Regulatory Toxicology and Pharmacology*, **2014**, 70, 519-26	3.4	35
24	Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors. *Pharmacogenomics*, **2013**, 14, 541-54	2.6	33
23	Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. *Clinical Gastroenterology and Hepatology*, **2009**, 7, 882-8	6.9	33
22	Drug rechallenge following drug-induced liver injury. *Hepatology*, **2017**, 66, 646-654	11.2	32
21	Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase*Regulatory Toxicology and Pharmacology*, **2015**, 72, 481-90	3.4	29
20	Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 268-278	6.1	26
19	Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. *Hepatology*, **2010**, 52, 2216-22	11.2	25
18	Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data. *Pharmacoepidemiology and Drug Safety*, **2013**, 22, 190-8	2.6	24
17	Effect of postoperative complications on health and employment following liver transplantation. *Clinical Transplantation*, **1998**, 12, 99-103	3.8	22
16	Background incidence of liver chemistry abnormalities in a clinical trial population without underlying liver disease. *Regulatory Toxicology and Pharmacology*, **2008**, 52, 85-8	3.4	20

15	Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration. *Digestive Diseases and Sciences*, **2018**, 63, 2259-2266	4	19
14	Regulation of rat hepatic cytochrome P450IIE1 in primary monolayer hepatocyte culture. *Xenobiotica*, **1991**, 21, 1621-31	2	18
13	Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?. *Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS*, **2019**, 36, 64-71	0.7	17
12	Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. *Regulatory Toxicology and Pharmacology*, **2018**, 94, 101-107	3.4	16
11	Liver disease in pregnancy. *American Family Physician*, **1999**, 59, 829-36	1.3	15
10	Childrenæ liver chemistries vary with age and gender and require customized pediatric reference ranges. *Regulatory Toxicology and Pharmacology*, **2015**, 73, 349-55	3.4	12
9	Validation of multivariate outlier detection analyses used to identify potential drug-induced liver injury in clinical trial populations. *Drug Safety*, **2012**, 35, 865-75	5.1	11
8	A pre-marketing ALT signal predicts post-marketing liver safety. *Regulatory Toxicology and Pharmacology*, **2012**, 63, 433-9	3.4	8
7	A proposed modification to Hyæ law and Edish criteria in oncology clinical trials using aggregated historical data. *Pharmacoepidemiology and Drug Safety*, **2013**, 22, 571-8	2.6	8
6	Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort. *Regulatory Toxicology and Pharmacology*, **2016**, 77, 257-62	3.4	4
5	The evaluation of drug rechallenge: the casopitant Phase III program. *Regulatory Toxicology and Pharmacology*, **2010**, 58, 539-43	3.4	3
4	APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.. *JAMA Internal Medicine*, **2022**,	11.5	2
3	Identifying and Treating Nonalcoholic Fatty Liver Disease. *Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS*, **2019**, 36, 20-29	0.7	1
2	Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. *Military Medicine*, **2016**, 181, 1375-1381	1.3	1
1	Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort. *Gut*, **2021**,	19.2	0